Healthcare Review: Alkermes Plc, Merck & Co, Omnicell, EDAP TMS, Medivation Print
By Mary Davila   
Friday, 01 February 2013 13:59
Stocks climbed to five-year highs on Friday in the wake of jobs and manufacturing data that showed the economy's sluggish recovery is still on track.

Data on Thursday showed investors poured $12.7 billion into U.S.-based stock mutual funds and exchange-traded funds in the latest week, concluding the strongest four-week flows into stock funds since 1996.

Following are notable movers at mid day on Friday:

Shares of Alkermes Plc. (NASDAQ:ALKS)
slipped 5% after pricing its 7.75M share secondary offering at $22.13, a 6.5% discount to yesterday's close. Jefferies acted as sole book running manager for the offering. Separately, BAML cuts the shares Neutral, but raises its price target from $23.00 to $24.00.

Merck & Co., Inc. (NYSE:MRK)
slips today after its Q4 fails to impress amid a decline in net sales. The company blames the earnings drop on patent expiry for its asthma drug Singulair, adding that the loss of its patent in the U.S. and Europe will be 2013's biggest revenue challenge. The company also announced a potential year-long delay in seeking regulatory approval for its new osteoporosis drug odanacatib, citing the need for additional safety and efficacy data from an ongoing clinical trial.

Shares of Omnicell, Inc. (NASDAQ:OMCL) jumps 10% higher today after a reporting record high Q4, with revenue coming in better than analysts expected. Total sales jumped 43% Y/Y, as the provider of inventory management systems for hospitals and other health-care facilities also posted a solid $155M backlog of business, up 16% from a year earlier.

gets a pop after submitting its Pre-Market Approval Application to the FDA for Ablatherm-HIFU, a high intensity ultrasound for the treatment of low risk, localized prostate cancer. Included in EDAP's submission is positive data from its Phase 3 clinical trials and encouraging statistics from its worldwide database of treatment information and follow-up data from patients who have already undergone the therapy.

Medivation, Inc. (NASDAQ:MDVN)
moves up today after its Japanese alliance partner Astellas Pharma reported in its financial results last night that it expects Xtandi sales to exceed year-end net sales targets ending on March 31. MDVN is due to report at the end of February. Separately, Jefferies raises its price target on the shares from $62 to $64. Shares of MDVN are up 4%.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus